The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 11.11%, which has investors questioning if this is right time ...

Adding intraperitoneal paclitaxel to intravenous paclitaxel and oral S-1 improved survival in patients with gastric cancer and peritoneal metastasis.

The authorisation allows the therapy to be used as a single agent for the maintenance treatment of adult individuals with advanced high-grade ovarian, fallopian tube or primary peritoneal cancer who ...

Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Zentalis Pharmaceuticals in a research note issued on Wednesday, February 5th. Leerink Partnrs ...

The move is part of a strategic restructuring aimed at getting azenosertib to the market for patients with gynecological ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib.

China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...

This is a drug to be used in the treatment of peritoneal cancer in people who have BRCA-mutated advanced ovarian, fallopian tube, or primary peritoneal cancer. The enzyme-blocking activity of Lynparza ...